(Stuttgart) - Insilico Biotechnology AG has announced that Prof. Dr.-Ing. René Schenkendorf has complemented its Scientific Advisory Board. With this further expansion of the board Insilico will be prepared to face the challenges presented by the high demand for biopharma digitalization.
Prof. Schenkendorf’s profound knowledge and experience will greatly enhance Insilico’s capability for developing ground breaking software solutions to serve its customers. Prof. Schenkendorf has been recently assigned the professorship "Smart Manufacturing/Industry 4.0" at the Harz University of Applied Sciences in Wernigerode, Germany. Since 2016, he has led the Pharmaceutical Process Systems Engineering group at the Institute for Energy and Process Systems Engineering at the Technische Universität Braunschweig. His research is focused on the Design of Experiments (DoE), digitalization of biopharmaceutical processes, hybrid modelling, and model-based process design under uncertainty.
Since 2007, Prof. Schenkendorf has authored and co-authored more than 70 publications demonstrating his significant research in the field of process systems engineering in the biopharmaceutical industry. His publications cover research in model-based experimental design, optimization, and robustification of biomanufacturing processes, including enzyme-catalysed reaction networks, bioreactor design, and downstream process units.
Klaus Mauch, CEO of Insilico, says: "Insilico is honored to have Prof. Schenkendorf as a member of the Scientific Advisory Board. His experience is instrumental to drive our technology to provide comprehensive solutions for biomanufacturing and realize our vision of the Smart Biofactory."
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality, and process robustness. Ground-breaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.